ATAI Life Sciences NV (9VC) — Financial Flexibility Index
ATAI Life Sciences NV (9VC) has a Financial Flexibility Index of -0.22x as of September 2025. Free cash flow of €-17.90 Million (operating CF €-23.26 Million minus capex €5.36 Million) represents 0% of total liabilities (€79.91 Million). Check 9VC strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
ATAI Life Sciences NV Financial Flexibility Index (2019–2024)
Historical Financial Flexibility Index trend for ATAI Life Sciences NV across 6 annual periods. See ATAI Life Sciences NV current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for ATAI Life Sciences NV (2019–2024)
Year-by-year free cash flow to debt coverage for ATAI Life Sciences NV. For the full company profile including market capitalisation, see 9VC market cap.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -1.92x | €-82.34 Million | €-82.44 Million | €42.83 Million | ▼ -13.1% |
| 2023 | -1.70x | €-83.53 Million | €-84.12 Million | €49.16 Million | ▲ +34.8% |
| 2022 | -2.61x | €-103.44 Million | €-104.47 Million | €39.67 Million | ▼ -18.4% |
| 2021 | -2.20x | €-62.12 Million | €-63.25 Million | €28.21 Million | ▼ -72.1% |
| 2020 | -1.28x | €-20.71 Million | €-20.77 Million | €16.18 Million | ▲ +59.5% |
| 2019 | -3.16x | €-7.83 Million | €-7.85 Million | €2.48 Million | — |